Trial Profile
A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD), Part I
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs PDC 1421 (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors BioLite Inc
- 19 Jan 2023 Results published in the ABVC Biopharma Media Release.
- 19 Jan 2023 According to a ABVC Biopharma media release, results from this trial were presented at the 2023 Conference of The American Professional Society of ADHD and Related Disorders (APSARD) Poster Session.
- 02 Feb 2022 Primary endpoint has been met. (Number of Participants With Improvement 40% in ADHD-RS-IV From Baseline up to 8 Weeks Treatment-low dose, 380mg), as per the ABVC Biopharma Media Release.